bioMérieux Celebrates New Regional Headquarters in Riyadh, Saudi Arabia
Oxford Nanopore and bioMérieux launch AmPORE-TB, a Research Use Only sequencing-based solution to rapidly characterize drug resistant-tuberculosis
bioMérieux has just acquired a stake in Allergen Alert, an innovative startup specializing in the rapid detection of food allergens for individuals and professionals.
Study will begin enrollment in Q1 2026 in the US and UK and leverage the BIOFIRE® SPOTFIRE® point-of-care diagnostics platform at U.S. sites.
bioMérieux strengthens its next-generation sequencing capabilities with the acquisition of Day Zero Diagnostics solutions and technologies
bioMérieux Recognized as Top 1% by S&P Global
bioMérieux receives U.S. FDA clearance for the new version of its molecular test targeting causes of gastroenteritis, BIOFIRE® FILMARRAY® Gastrointestinal (GI) Panel Mid
BIOFIRE® FILMARRAY® Tropical Fever Panel, a syndromic PCR test targeting causes of tropical fever infections, receives U.S. FDA Special 510(k) clearance
Representatives John Curtis (R-UT) and Blake Moore (R-UT) toured bioMérieux.
Malawi Ministry of Health, bioMérieux, and Pfizer Form Country’s First Multisectoral Collaboration to Help Address Antimicrobial Resistance
Dual 510(k) clearance and CLIA-waiver approval for the BIOFIRE® SPOTFIRE® R/ST Panel
bioMérieux announces nomination of two new Executive Committee members to lead Medical Affairs and R&D